Myriad Genetics, Inc. (MYGN): Price and Financial Metrics


Myriad Genetics, Inc. (MYGN): $30.54

-1.09 (-3.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYGN POWR Grades


  • Value is the dimension where MYGN ranks best; there it ranks ahead of 69.62% of US stocks.
  • The strongest trend for MYGN is in Value, which has been heading down over the past 31 weeks.
  • MYGN's current lowest rank is in the Momentum metric (where it is better than 16.13% of US stocks).

MYGN Stock Summary

  • The price/operating cash flow metric for Myriad Genetics Inc is higher than 94.8% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -26.05%, Myriad Genetics Inc's debt growth rate surpasses merely 18.98% of about US stocks.
  • As for revenue growth, note that MYGN's revenue has grown -25.59% over the past 12 months; that beats the revenue growth of merely 14.55% of US companies in our set.
  • Stocks that are quantitatively similar to MYGN, based on their financial statements, market capitalization, and price volatility, are XONE, SPOK, SNOA, RES, and VRM.
  • Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to myriad.com.

MYGN Valuation Summary

  • In comparison to the median Healthcare stock, MYGN's EV/EBIT ratio is 149.81% lower, now standing at -13.3.
  • MYGN's price/sales ratio has moved down 19.8 over the prior 243 months.
  • MYGN's price/sales ratio has moved down 19.8 over the prior 243 months.

Below are key valuation metrics over time for MYGN.

Stock Date P/S P/B P/E EV/EBIT
MYGN 2020-11-10 2.1 1.4 -6.6 -6.2
MYGN 2018-04-25 2.5 2.2 15.2 15.9
MYGN 2018-03-13 2.6 2.2 15.6 16.3
MYGN 2014-03-07 3.8 4.1 14.8 9.2
MYGN 2008-07-14 12.2 7.3 -101.2 -95.6
MYGN 2003-09-02 5.4 2.0 -13.8 -10.8

MYGN Growth Metrics

  • Its year over year price growth rate is now at 93.32%.
  • The 2 year revenue growth rate now stands at -2.24%.
  • Its 2 year net income to common stockholders growth rate is now at -207.93%.
MYGN's revenue has moved down $206,500,000 over the prior 34 months.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 566.1 28.1 -148
2020-12-31 557 -26.9 -223.7
2020-09-30 597.5 -14.4 -194.1
2020-06-30 638.6 60.7 -199.5
2020-03-31 760.8 62.2 -148.3
2019-12-31 813.4 52 -26.2

MYGN Price Target

For more insight on analysts targets of MYGN, see our MYGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.63 Average Broker Recommendation 2.1 (Hold)

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $30.54 52-week high $34.02
Prev. close $31.63 52-week low $11.76
Day low $30.50 Volume 94,868
Day high $31.96 Avg. volume 676,490
50-day MA $30.45 Dividend yield N/A
200-day MA $25.75 Market Cap 2.35B

Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.

MYGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$30.54$0.09 -100%

We started the process of determining a valid price forecast for Myriad Genetics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Myriad Genetics Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Myriad Genetics Inc ended up being:

  • In the past 5.73 years, Myriad Genetics Inc has a compound free cash flow growth rate of -0.34%; that's higher than only 4.88% of free cash flow generating stocks in the Healthcare sector.
  • Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -15.98. This coverage rate is greater than that of only 5.1% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-100%
1%-100%
2%-100%
3%-100%
4%-100%
5%-100%

Want more companies with a valuation profile/forecast similar to that of Myriad Genetics Inc? See AGHC, AMYT, CRY, CSTL, and EDAP.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021, at 4:30 p.m. EDT on Tuesday, August 3, 2021. The company’s quarterly earnings will be released prior to the market opening on August 3, 2021. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provi

Yahoo | July 28, 2021

Were Hedge Funds Right About Myriad Genetics, Inc. (MYGN)?

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

Yahoo | July 28, 2021

New research reveals most Americans can’t identify the symptoms of depression

GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depressionSALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor. The survey found that nearly one in two adults are very confident they would recognize if a loved one is suffering from depression. H

Yahoo | July 28, 2021

Myriad Genetics supports new ACMG recommendation on genetic carrier screening

Myriad Genetics (MYGN) announces its support for a new recommendation statement by the American College of Medical Genetics and Genomics ((ACMG)), advising that genetic carrier screening be offered to all people who are pregnant or considering a pregnancy.The statement recommends screening for more than 110 genetic disorders regardless of family history or...

Seeking Alpha | July 21, 2021

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement by the American College of Medical Genetics and Genomics (ACMG), advising that genetic carrier screening be offered to all people who are pregnant or considering a pregnancy. The statement recommends screening for more than 110 genetic disorders regardless of family history or ethnicity. ACMG pre

Yahoo | July 21, 2021

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo -2.43%
3-mo -3.42%
6-mo 4.48%
1-year 153.02%
3-year -30.59%
5-year -2.80%
YTD 54.44%
2020 -27.38%
2019 -6.33%
2018 -15.36%
2017 106.03%
2016 -61.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.967 seconds.